Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT COLEMAN and SIQING FU.
Connection Strength
0.583
-
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
Score: 0.140
-
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79.
Score: 0.126
-
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.
Score: 0.105
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.095
-
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
Score: 0.055
-
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773.
Score: 0.042
-
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80.
Score: 0.019